What is HC Wainwright's Forecast for NKTR Q1 Earnings?

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Nektar Therapeutics in a research report issued to clients and investors on Tuesday, December 10th. HC Wainwright analyst A. He forecasts that the biopharmaceutical company will post earnings per share of ($0.17) for the quarter. HC Wainwright currently has a "Buy" rating and a $6.50 target price on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.75) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q2 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.65) EPS, FY2026 earnings at ($0.72) EPS, FY2027 earnings at ($0.87) EPS and FY2028 earnings at ($0.79) EPS.

NKTR has been the subject of several other research reports. Piper Sandler started coverage on shares of Nektar Therapeutics in a research report on Monday, November 4th. They issued an "overweight" rating and a $7.00 price objective for the company. BTIG Research reiterated a "buy" rating and issued a $4.00 price target on shares of Nektar Therapeutics in a report on Monday, September 30th. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $4.10.

Nektar Therapeutics Stock Performance

NASDAQ NKTR remained flat at $1.02 during trading on Wednesday. The company's stock had a trading volume of 1,738,035 shares, compared to its average volume of 1,797,385. Nektar Therapeutics has a 12 month low of $0.46 and a 12 month high of $1.93. The firm has a market capitalization of $188.15 million, a P/E ratio of -1.21 and a beta of 0.57. The stock has a fifty day moving average price of $1.23 and a 200 day moving average price of $1.26.

Institutional Trading of Nektar Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. SG Americas Securities LLC lifted its holdings in Nektar Therapeutics by 30.4% during the 3rd quarter. SG Americas Securities LLC now owns 95,637 shares of the biopharmaceutical company's stock worth $124,000 after buying an additional 22,285 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Nektar Therapeutics in the 2nd quarter worth approximately $29,000. Valence8 US LP bought a new stake in shares of Nektar Therapeutics in the 3rd quarter valued at $34,000. Jane Street Group LLC increased its position in shares of Nektar Therapeutics by 50.0% during the third quarter. Jane Street Group LLC now owns 91,470 shares of the biopharmaceutical company's stock worth $119,000 after buying an additional 30,481 shares during the period. Finally, Intech Investment Management LLC bought a new position in Nektar Therapeutics during the third quarter worth $41,000. 75.88% of the stock is currently owned by institutional investors.

Nektar Therapeutics Company Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.